e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

London, UK, 05 February 2025 – e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026.  

Presentation Details 

Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B 
Format: Oral Presentation  
Presentation Number: OR10 
Date: 7th February 2025 
Session: SLAM